Sriram Ryali
Insider
First SEC filing: Jan. 2, 2024 · Latest: Jan. 2, 2024
Insider at
Insider transactions
0 buys (P)
0 sells (S)
Net: $0
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Feb. 20, 2026 | CRBU | A | 55,000 | · | · | 72,360 Direct | +316.82% | Acquired | (price as of 2026-10-02) |
| Feb. 20, 2026 | CRBU | A | 247,500 | · | · | 247,500 Direct | · | Acquired | (price as of 2026-10-02) |
| Jan. 29, 2025 | CRBU | P | 17,360 | $1.42 | $24,651 | 17,360 Direct | · | Acquired | -14.1% (price as of 2026-10-02) |
| Jan. 10, 2025 | CRBU | A | 300,000 | · | · | 300,000 Direct | · | Acquired | (price as of 2026-10-02) |
| Jan. 1, 2024 | CDXS | A | 314,125 | · | · | 314,125 Direct | · | Acquired | (price as of 2026-10-02) |
| Jan. 1, 2024 | CDXS | A | 52,350 | · | · | 175,791 Direct | +42.41% | Acquired | (price as of 2026-10-02) |
| Sept. 8, 2023 | CDXS | P | 11,650 | $1.70 | $19,805 | 123,441 Direct | +10.42% | Acquired | -20.0% (price as of 2026-10-02) |
| Feb. 10, 2023 | CDXS | A | 111,791 | · | · | 111,791 Direct | · | Acquired | (price as of 2026-10-02) |
| Feb. 10, 2023 | CDXS | A | 372,637 | · | · | 372,637 Direct | · | Acquired | (price as of 2026-10-02) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Feb. 20, 2026 | CRBU | Option to purchase Common Stock | Common Stock | $1.80 | Feb. 19, 2036 | 247,500 | Acquired |
| Jan. 10, 2025 | CRBU | Option to purchase Common Stock | Common Stock | $1.64 | Jan. 9, 2035 | 300,000 | Acquired |
| Jan. 1, 2024 | CDXS | Stock Option (Right to Buy) | Common Stock | $3.05 | Jan. 1, 2034 | 314,125 | Acquired |
| Feb. 10, 2023 | CDXS | Stock Option (Right to Buy) | Common Stock | $5.86 | Feb. 10, 2033 | 372,637 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2024 | $354,202 | · | · | · | $173,812 | · | $163,379 | $1,483,677 |
| 2023 | $423,438 | $100,000 | · | · | $232,891 | · | $14,120 | $2,780,191 |
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2025 | $483,163 | $164,900 | · | · | · | · | $14,000 | $1,029,413 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.